Interferon-α

Interferon-α Reactions 1704, p203 - 2 Jun 2018 Type 1 diabetes mellitus: case report A 59-year-old woman developed type 1 diabetes mellitus following treatment with interferon α [route and dosage not stated]. The woman, who had been diagnosed with nodular malignant melanoma, was receiving treatment with low doses of interferon α. She presented to hospital for excessive thirst, fatigue, polyuria and weight loss. Fifteen months following the interferon α treatment, her fasting plasma glucose level found to be elevated. She was found to have symptoms of polydypsia and polyuria. She did not have a previous history of glucose intolerance. Thereafter, her plasma glucose level elevated to 1126mg/dL with serum glycosylated haemoglobin of 12.4%. Antibodies to glutamic acid decarboxylase and islet antigen-2 were negative. From these findings, she was diagnosed with type 1 diabetes mellitus, which was considered to be related to interferon α. She was admitted and received treatment with insulin and volume substitution as a counter-regulation. Three days following admission, she was shifted to the general inpatient department. Her glucose level returned to normal. The woman’s treatment with interferon α was discontinued. She was treated with insulin. At a one year follow-up, her type 1 diabetes mellitus persisted. Author comment: "To the best of our knowledge, this is the first reported case of low-dose [interferon-alfa]-induced type 1 diabetes." Sossau D, et al. Type 1 diabetes mellitus caused by treatment with low-dose interferon-alpha in a melanoma patient. Melanoma Research 27: 516-518, No. 5, 19 Jul 2017. Available from: URL: http://doi.org/10.1097/ CMR.0000000000000381 - Germany 803322946 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Interferon-α

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/interferon-UDhPka7CdD
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-018-46846-4
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p203 - 2 Jun 2018 Type 1 diabetes mellitus: case report A 59-year-old woman developed type 1 diabetes mellitus following treatment with interferon α [route and dosage not stated]. The woman, who had been diagnosed with nodular malignant melanoma, was receiving treatment with low doses of interferon α. She presented to hospital for excessive thirst, fatigue, polyuria and weight loss. Fifteen months following the interferon α treatment, her fasting plasma glucose level found to be elevated. She was found to have symptoms of polydypsia and polyuria. She did not have a previous history of glucose intolerance. Thereafter, her plasma glucose level elevated to 1126mg/dL with serum glycosylated haemoglobin of 12.4%. Antibodies to glutamic acid decarboxylase and islet antigen-2 were negative. From these findings, she was diagnosed with type 1 diabetes mellitus, which was considered to be related to interferon α. She was admitted and received treatment with insulin and volume substitution as a counter-regulation. Three days following admission, she was shifted to the general inpatient department. Her glucose level returned to normal. The woman’s treatment with interferon α was discontinued. She was treated with insulin. At a one year follow-up, her type 1 diabetes mellitus persisted. Author comment: "To the best of our knowledge, this is the first reported case of low-dose [interferon-alfa]-induced type 1 diabetes." Sossau D, et al. Type 1 diabetes mellitus caused by treatment with low-dose interferon-alpha in a melanoma patient. Melanoma Research 27: 516-518, No. 5, 19 Jul 2017. Available from: URL: http://doi.org/10.1097/ CMR.0000000000000381 - Germany 803322946 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off